Omentin and chemerin and their association with obesity in women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 30, Issue 6, 2014, Pages 419-422

  Guzel, Eda Celik ^a   Celik, Cem ^a   Abali, Remzi ^a   Kucukyalcin, Volkan ^a   Celik, Elcin ^a   Guzel, Murat ^b   Yilmaz, Murat ^a  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

^b AHI EVRAN UNIVERSITY   (Turkey)

Author keywords

Androgen; Chemerin; Insulin resistance; Omentin; Polycystic ovary syndrome

Indexed keywords

ADIPOCYTOKINE; CHEMERIN; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROGESTERONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; OMENTIN; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHEMERIN, HUMAN; CHEMOKINE; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FAT MASS; FEMALE; FOLLITROPIN BLOOD LEVEL; GESTAGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; YOUNG ADULT; ADOLESCENT; BLOOD; CROSS-SECTIONAL STUDY; DOWN REGULATION; OUTPATIENT DEPARTMENT; PATHOPHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; TURKEY; UNIVERSITY HOSPITAL; UPREGULATION; WAIST HIP RATIO;

ADIPOSITY; ADOLESCENT; ADULT; BODY MASS INDEX; CHEMOKINES; CROSS-SECTIONAL STUDIES; CYTOKINES; DOWN-REGULATION; FEMALE; GPI-LINKED PROTEINS; HOSPITALS, UNIVERSITY; HUMANS; INSULIN RESISTANCE; LECTINS; OBESITY; OUTPATIENT CLINICS, HOSPITAL; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; TURKEY; UP-REGULATION; WAIST-HIP RATIO; YOUNG ADULT;

EID: 84901217478     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.888412     Document Type: Article

References (34)

1. Diamanti Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J of Clin endocrinol Metabol 1999; 84:4006-11. (Pubitemid 30644187
2. Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Bailliere's Clin Endocrinol Metabol 1996;10:221-47. (Pubitemid 26166053
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrin Rev 1997; 18:774-800. (Pubitemid 28009567
4. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabet Care 1999;22:141-6. (Pubitemid 29028311
5. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metabol 1999;84: 165-9. (Pubitemid 29036695
6. Celik C, Abali R, Bastu E, et al. Assessment of impaired glucose tolerance prevalence with hemoglobin A(1)c and oral glucose tolerance test in 252 Turkish women with polycystic ovary syndrome: A prospective, controlled study. Hum Reprod 2013;28: 1062-8
7. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Amer J Med 2001;111:607-13. (Pubitemid 34088070
8. Banaszewska B, Duleba AJ, Spaczynski RZ, et al. Lipids in polycystic ovary syndrome: Role of hyperinsulinemia and effects of metformin. Amer J Obstet Gynecol 2006;194:1266-72
9. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: Roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metabol 2001;86:66-71. (Pubitemid 32109777
10. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74. (Pubitemid 19250404
11. Arner P. Insulin resistance in type 2 diabetes-role of the adipokines. Curr Molec Med 2005;5:333-9. (Pubitemid 40663138
12. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nat 1994;372:425-32. (Pubitemid 24365442
13. Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884-8. (Pubitemid 34564302
14. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12. (Pubitemid 32151228
15. Schaffler A, Neumeier M, Herfarth H, et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005;1732:96-102. (Pubitemid 43267310
16. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Amer J Physiol Endocrinol Metabol 2006;290:1253-61
17. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-94. (Pubitemid 47481514
18. Yilmaz Y, Yonal O, Kurt R, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011;46:91-7
19. Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metabol 2009;94:3085-8
20. Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol 2010;72:342-8
21. Ress C, Tschoner A, Engl J, et al. Effect of bariatric surgery on circulating chemerin levels. Europ J Clin Invest 2010;40: 277-80
22. Revised 2003 consensus on diagnostic criteria and long-Term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7
23. Coskun A, Ercan O, Arikan DC, et al. Modified Ferriman-Gallwey hirsutism score and androgen levels in Turkish women. Europ J Obstet, Gynecol, Rep Biol 2011;154:167-71
24. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19. (Pubitemid 15018832
25. Chu SH, Lee MK, Ahn KY, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PloS One 2012;7: 34710
26. Tan BK, Chen J, Farhatullah S, et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009;58: 1971-7
27. Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: Ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008;57:801-8
28. Xiaotao L, Xiaoxia Z, Yue X, et al. Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Art Dis 2012;23:412-16
29. Jialal I, Devaraj S, Kaur H, et al. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J ClinEndocrinol Metabol 2013;98:514-17
30. Wang Q, Kim JY, Xue K, et al. Chemerin, a novel regulator of follicular steroidogenesis and its potential involvement in polycystic ovarian syndrome. Endocrinol 2012;153:5600-11
31. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Japan Acad Ser B, Phys Biol Sci 2010;86:131-41
32. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992;36: 105-11
33. Holte J, Bergh T, Berne C, et al. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metabol 1995;80:2586-93
34. Moreno-Navarrete JM, Catalan V, Ortega F, et al. Circulating omentin concentration increases after weight loss. Nutrit Metabol 2010;7:27